| Project/Area Number |
08407039
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
WATANABE You School of Medicine Department of Surgery (1) Kanazawa University Professor., 医学部, 教授 (20019897)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHTA Yasuhiko Kanazawa University Hospital, Department of Surgery (1), Assistant, 医学部・附属病院, 助手 (00272964)
ODA Makoto Kanazawa University Hospital, Department of Surgery (1), Assistant, 医学部・附属病院, 助手 (50224241)
MURAKAMI Sinya School of Medicine, Department of Surgery (1), Speaker., 医学部, 講師 (20210007)
関戸 伸明 金沢大学, 医学部・附属病院, 助手 (10293359)
林 義信 金沢大学, 医学部・附属病院, 助手 (00251950)
|
|---|
| Project Period (FY) |
1996 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥16,200,000 (Direct Cost: ¥16,200,000)
Fiscal Year 1998: ¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 1997: ¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 1996: ¥10,600,000 (Direct Cost: ¥10,600,000)
|
|---|
| Keywords | Lung cancer / VEGF / Micrometastasis / PAI-2 / Angiogenesis / cytokeratin / bcl-2 / P53 / PAI-2 / p53 / bcl-2 / MT-MMP-1 |
|---|
| Research Abstract |
1.) As a result of immunohistochemical study, the bcl-2 protein expression in epidermoid carcinoma was higher than that in adenocarcinoma. In epidermoid carcinoma, a bcl-2 protein expressing group showed a better survival rate than a non-expressing group. A p53 protein positive group showed a poorer survival rate than a negative group. The bcl-2 expression in epidermoid carcinoma patients is a potentially valuable prognostic factor. And p53 protein might be a valuable prognostic indicator in non-small cell lung cancer, particularly in adenocarcinoma.
2) The expression of u-PA, u-PAR, and PAT-1 was detected in approximately 80% of lung cancers. A diminished expression level of PAI-2 was significantly correlated with lymph node metastasis and a poor prognosis. The expression of PAI-2 may be useful as a marker for evaluating the prognosis of lung cancer.
3) Using monoclonal antibodies against cytokeratin (CK) and a novel immunohistochemical method for the detection of CK positive tumor cells, we examined disseminated tumor cells in the bone marrow and lymph nodes of primary lung cancer patients. Lymphatic micrometastases and bone marrow micrometastases were detected in 27.3% and 23.5% of lung cancer patients, respectively. After revised staging based on the sites of nodal micrometastases, patients with stage II or stage IIIA disease showed significantly poorer survival rates than those with stage I disease. A significant correlation was found between the reduced E-cadherin expression in primary sites and nodal micrometastases.
4) In lung cancer tissue samples, the expression of VEGF mRNA was found at a high rate independent of histological subtypes. Among the four splicing variants, VEGF121 and 165 were the dominant types. As a marker of tumor angiogenesis, the VEGF expression level may be a significant prognostic indicator of lung cancers in early stages.
|
